ERCC1 Antibodies

Santa Cruz Biotechnology supplies a comprehensive collection of ERCC1 monoclonal antibodies for research focused on understanding DNA repair mechanisms. ERCC1 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). ERCC1, or Excision Repair Cross-Complementation Group 1, functions as a key component in the nucleotide excision repair pathway, maintaining genomic stability. ERCC1 actively participates in repairing DNA damage caused by environmental factors and influences cellular responses to chemotherapy. Research involving ERCC1 continues to advance our understanding of cancer biology and therapeutic development. Scientists worldwide utilize ERCC1 monoclonal antibodies to investigate DNA repair pathways and their impact on cellular health. ERCC1 research has revealed significant insights into cancer resistance mechanisms and potential therapeutic targets. Ongoing studies of ERCC1 contribute to developing more effective cancer treatments and understanding DNA repair processes. Santa Cruz Biotechnology monoclonal antibodies support researchers in advancing scientific knowledge and developing innovative therapeutic strategies.